The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 8th
This year, Kalorama has published its eighth edition of this informative volume based on the
market events of 2011. The report is over 1400 pages, reflecting the dramatic change in
IVD. New entrants, net technologies have entered the stage and all important events are
cataloged in this report. The idea behind Kalorama's unique report is that the entire market can
be captured in one volume and business planners avoid multiple purchases. Published every two
years, this volume includes coverage of the most important aspects of all of the major segments
of clinical lab testing, including:
Point of Care (POC), (Professional and Self-Testing)
Histology and Cytology (Pap, ISH, IHC, traditional non-pap, HPV)
Core Lab (General Chemistries, Workstations, Analyzers)
Immunoassays (Blood Gases, Urinalysis, Critical Care)
Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology,
Pharmacodiagnostics, Tissue Typing, Prenatal)
Coagulation (Lab-Based, POC, Genetic Markers)
Microbiology and Virology
Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
Market sizes, forecasts and shares are provided, as well as a geographic breakdown of the
segments, where possible. Changes in technology development, regulatory and reimbursement
issues, clinical care, and business environments are discussed. Current market numbers are
presented for 2011, with projections given through 2016.
The "Bible of the IVD Industry"
Now in 8 editions, this report has become the go-to market research reference for the
industry. Many of the top IVD companies use this product for business planning, which means
that this volume can provide a uniform standard for in vitro diagnostic market numbers. This
edition greatly expands coverage of the field and tracks the most important developments. See
aspects of the industry that might not be available in your company's internal resources. View
the market from an independent point of view. Learn about competitors in away that may be
invisible to internal personnel. Know the market players - your competitors and potential
partners, in proper context and classification. Save countless hours of staff time and other
research expenses with the authoritative guide for IVD market estimates and forecasts.
A Global Report
From the first edition, this report was designed as a global resource in order to give market-
watchers a true picture of the industry. IVD is a worldwide business. While the US is a large
healthcare market, much of the dynamism, the growth, and also competition is occurring in other
areas. Many of the most interesting opportunities for companies are occurring in emerging
markets. As part of its coverage, the report breaks down the entire IVD market for the following
Europe (EU countries, incl. IVD market sizes by country)
Asia (Japan, China and India)
Rest of World
A Report Designed for a Changing Industry
A number of totally disparate phenomena have come together to change the IVD industry.
Human genome research is finding links between a person's genome and several lifestyle
situations such as nutrition, dieting, skin conditions and other essentially non-medical conditions.
This has attracted consumer product companies such as Proctor & Gamble and Nestle to develop
products and services based on IVD technologies. Decreases in life science grants has
encouraged companies active in this space to migrate their technologies for clinical applications.
The result is the entry of companies such as Caliper Life Sciences, Illumina, Affymetrix and
Life Technologies to the diagnostics market with products and test services. Miniaturization of
traditional immunoassay and molecular test technologies has finally matured to the point where
they may be ready for scale-up and then commercialization into products. Here electronics
companies such as Sony, Samsung, Dell Computers and Intel Corp. have invested in clinical
diagnostics ventures. These exciting developments join expansion into new market segments by
companies already involved in the IVD industry.
In 2010 and 2011, there were at least 74 acquisitions and some 36 distribution agreements. And
this is only a small portion of what is really happening. There are many more deals that have not
been announced. The goal is to build better tests and stronger companies. The future of the
industry lies in the development of more sensitive, faster, user-friendly, IT capable devices for a
host of new protein and molecular markers.
In this eighth edition of The Worldwide Market for In Vitro Diagnostic Tests Kalorama
Information addresses all of the key issues affecting the diagnostic industry in 2012 and how
competitors are faring. Among the topics tackled in this report:
Molecular diagnostics including infectious disease mdx, pharmacodiagnostics, molecular poc
and test services are put in a context.
Merging IT and IVD: Establishing the EMR Record from IVD Tests
Healthcare Reform and its Possible Impact on IVD.
The Status of Automation in the Lab; Core Lab Section Includes Both Workstation and
Automated Panel Revenues.
Mass Spec, Next Gen Sequencing and Other Technology Entrants
Hospital Infection Testing - the latest
Several Hundred Company profiles. Top tier companies, Second and Third Tier
companies but also Smaller Innovators. The report`s profiles distinguish between
companies that are leaders in all aspects of IVD, those that are Specialists in one
particular area or a few.
Major Mergers as well as Partnerships, Distribution Agreements.
Brazil, India and China - Important Emerging Markets for IVD.
Innovations in Blood Banking
Histology/Cytology innovations; the role of FISH testing and Digital Images
Healthcare statistics for various countries -healthcare spending as a percent of GDP, new
hospitals, cost increases and other information.
Tables that document the most competitive products on the market and under
development in each area of IVD.
Country-level Breakout of IVD market for major European and Asian countries.
The Current Economic Situation
Update on the Regulation of Novel Devices
Buy your copy of this report @ http://www.reportsnreports.com/reports/183811-the-worldwide-
Published: July 2012
No. of Pages: 1400
Price : Single User License: US$ 6500 Price : Corporate User License: US$ 13000
Table of contents
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction - Doing more with less
Scope and Methodology
Size and Growth of the Market
CHAPTER TWO: INTRODUCTION
Lab Medicine Disciplines And Applications
Market Analysis of IVD Market Segments
The lure of IVD - new majors and entrants
Licenses and distribution agreements
Top Suppliers and Niche players
Point of View
CHAPTER THREE: OVERVIEW OF GLOBAL IN VITRO DIAGNOSTIC MARKETS
Population and Disease Demographics, Worldwide
Chronic Diseases as a Market Driver
The BRIC Effect
World Segments of the IVD Market and IVD Market Evolution
Specific Country Information
The United States of America - a world in flux
The Patient Protection and Affordable Care Act
Accountable Care Organizations
Accent on Preventative Care
In Patient Bundling
Molecular test reimbursement
Europe - effects of austerity
IVD Directive Update
CHAPTER FOUR: TRENDS AND INNOVATION
Looking to the East
Looking Past the Hospital ER
Telemedicine and Home Care Trends
Commercialization of Novel Tests
Wireless Connectivity and Healthcare Efficiencies
The search for non-invasive tools
CHAPTER FIVE: POINT-OF-CARE TEST PLATFORMS
Overview of POC Tests
The Major POC Test Players
Blood Glucose Monitoring
Blood Glucose Self Testing
Continuous Self Testing
Blood Glucose Testing by Professionals
Diabetes Testing - Glycated Hemoglobin
The Genetics of Diabetes
The Commercial Outlook for POC Tests
CHAPTER SIX: THE CORE LAB
Core Lab Overview
Overview of Chemistry Tests
Market Analysis : Leading Suppliers and Growth Potential
Critical Care Analysis
The Commercial Outlook for the Core Lab
CHAPTER SEVEN: IMMUNOASSAYS
Overview of Immunoassays
Immunoassay Test Segments - Mature and Emerging
Point-of-care OTC and Professional Use
The Commercial Outlook for Immunoassays
CHAPTER EIGHT: MOLECULAR ASSAY PLATFORMS
Overview of Molecular Assays
Worldwide Opportunities for Molecular Tests
Molecular Test User Markets
Next generation Sequencing
Molecular Technologies And Players
Prenatal Chromosome Analysis
The Commercial Outlook for Molecular Tests
CHAPTER NINE: HEMATOLOGY
Overview of Hematology
Automation and IT
Decentralized Hematology Testing
Market Analysis : Leading Suppliers
The Commercial Outlook for Hematology Tests
CHAPTER TEN: COAGULATION
Overview of Coagulation / Immunohematology Tests
Genetics and Personalized Medicine
Genetic markers of hypercoagulopathies
Decentralized Coagulation testing - Professional Use
Decentralized Coagulation testing - OTC
The Commercial Outlook for Coagulation Tests
CHAPTER ELEVEN: MICROBIOLOGY AND VIROLOGY
Overview of Microbiology / Virology Tests
Antimicrobial Drug Resistance
Genome Sequencing and Mass Spectrometry
Microbial Identification and Antimicrobial Sensitivity Tests
Immunoassays - lab based
Immunoassays - rapid
The Commercial Outlook for Microbiology / Virology Tests
CHAPTER TWELVE: BLOOD BANKING SERVICES
Overview of Blood Banking
Blood Management - are all these transfusions good medicine
Nucleic Acid Testing Continues to Grow
The Commercial Outlook for Blood Banking
CHAPTER THIRTEEN: HISTOLOGY AND CYTOLOGY
Overview of Histology / Cytology
Companies expand with test services
Pap and HPV Tests
Immunochemistry and In Situ Hybridization
Circulating Tumor Cells
The Commercial Outlook for Histology and Cytology Tests
CHAPTER FOURTEEN: The Top Tier
Beckman Coulter Inc.
Becton, Dickinson and Company (BD)
Bio-Rad Laboratories Inc.
Instrumentation Laboratory (IL)
Ortho Clinical Diagnostics
Siemens Healthcare Diagnostics
Thermo Fisher Scientific Inc.
CHAPTER FIFTEEN: The Second Tier
Agilent Technologies Inc.
Bruker BioSciences Corporation
China Medical Technologies
Eiken Chemical Co., Ltd
Fujirebio Diagnostics, Inc.
General Electric - GE Healthcare
IRIS International, Inc.
A. Menarini Diagnostics
Mindray Bio-Medical Electronics Co., Ltd
Randox Laboratories Ltd.
Transasia Bio-Medicals Ltd.
Trinity Biotech plc
Ventana Medical Systems Inc.
Wako Pure Chemical Industries, Ltd.
Werfen Group S.A
Contact: email@example.com for further details.